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VasculopathyAbstract Background: Advanced glycation end products (AGEs) are a heterogeneous and com-
plex group of biochemical compounds, resulting from nonenzymatic glycation and oxidation of
protein, nucleic acids, and lipids.
Aim of the study: To assess sRAGE and CIMT in patients with T1DM and their relation to gly-
cemic control and diabetic vascular complications.
Patients & methods: This study included 60 patients with mean age of 14.4 ± 3.4 years. They
were subdivided into complicated and non complicated groups according to the presence of micro-
vascular complications. Thirty age and sex matched controls were included. Patients with disease
duration less than 5 years, connective tissue disease, liver dysfunction, or apparent cardiovascular
disease and those on lipid lowering agents were excluded. Laboratory investigations included;
HbA1c%, urinary albumin excretion (UAE), fasting lipid proﬁle and sRAGE. Mean CIMT was
measured by dopplex ultrasound.
362 E.M. Sherif et al.Results: Patients had higher sRAGE (1765.0 ± 451.0 pg/ml) (p< 0.001) especially the non
complicated group (p= 0.18). It was directly correlated to HDL (r= 0.3, p= 0.012). Patients
had increased CIMT (0.57 ± 0.14 mm) (p< 0.001) with 13.3% having carotid wall abnormalities.
CIMT was directly correlated to age, weight, BMI, systolic and diastolic blood pressures, UAE,
cholesterol and LDL (p< 0.05) and inversely correlated to HDL (p< 0.05). Neither CIMT nor
sRAGE were correlated to glycemic control or disease duration.
Conclusion: Patients with T1DM are at risk of increased CIMT with a concomitant increase in
sRAGE which may be a therapeutic target for the prevention of diabetic vascular complications.
 2014 Production and hosting by Elsevier B.V. on behalf of Ain Shams University.1. Introduction
Advanced glycation end products (AGEs) represent a family
of proteins, peptides, amino acids, nucleic acids and lipid
adducts formed by the reaction of carbonyl compounds
derived directly or indirectly from glucose, ascorbic acid and
other metabolites such as methylglyoxal. AGEs formation in
diabetes is of growing importance for their role as markers
and potential culprits of diabetic complications, in particular
retinopathy, nephropathy and neuropathy [1]. Receptor for
AGEs (RAGE) is a cell-bound receptor of the immunoglobu-
lin superfamily, which may be activated by a variety of proin-
ﬂammatory ligands. AGEs bind to RAGE, thereby leading to
activation of a range of inﬂammatory and ﬁbrotic pathways
causing tissue injury [2]. Soluble RAGE (sRAGE), arising
from ectodomain shedding of membrane RAGE and secretion
of spliced variants, counteracts the pathogenic effect of
AGE-RAGE signaling by acting as a decoy of AGEs [3].
Investigating AGEs–RAGE axis may facilitate spiraling
toward pathology of many fronts including cardiovascular
disease (CVD) development [4]. The aim of this study is to
evaluate sRAGE level in children and adolescents with type
1 diabetes mellitus and its possible relation to glycemic control,
diabetic vascular complications as well as carotid intima-media
thickness as a marker of atherosclerosis.
2. Patients
The present study is a case control study. It was conducted at
the Pediatric Diabetes Clinic, Children’s Hospital; Ain Shams
University in the period from April 2011 to April 2012. It
included 60 patients with type 1 diabetes mellitus of more than
5 years duration from those who regularly attend the clinic.
Their ages ranged from 6 to 18 years with the mean age of
14.4 ± 3.4 years. There were 40 females and 20 males. Any
patient with type 2 diabetes mellitus, BMI more than 95th per-
centile (according to Egyptian growth charts) [5], patients with
malignancy, connective tissue disease, liver dysfunction, renal
dysfunction (serum creatinin > 1.2 mg/dl), apparent cardio-
vascular disease or taking any oral hypoglycemic, antiplatelet
or lipid lowering medications were excluded from the study.
Patients were further subdivided into two groups according
to the presence of microvascular complications; Group I:
Thirty patients with diabetic microvascular complications
(nephropathy n= 10, retinopathy n= 6 and/or neuropathy
n= 24). Group II: Thirty patients without diabetic microvas-
cular complications. Thirty age and sex matched healthy
individuals were included as a control group. A written
informed consent was taken from all patients or their legalguardians. The work is carried out in accordance with The
Code of Ethics of the World Medical Association (Declaration
of Helsinki) for experiments involving humans. Data collected
from patients included; demographic data, disease duration,
insulin type and dose (Unit/kg/day), monitoring of treatment
and symptoms suggestive of any diabetic complications. Com-
plete physical examination included; Vital signs, anthropomet-
ric measures plotted against Egyptian percentile for age and
sex, body mass index (BMI) and sexual maturity rating accord-
ing to Tanner’s classiﬁcation [6]. Fundus examination was also
done.
3. Methods
Laboratory investigations included; Mean random blood glu-
cose by enzymatic method on Hitashi instruments. Glycosyl-
ated Hemoglobin (HbA1c%) was calculated using HPLC
(High performance liquid chromatography) and the mean
value over the last year follow up was calculated [7]. Urinary
albumin excretion (UAE) was measured; using the immuno-
turbidimetric method [8]. Fasting serum lipid proﬁle [choles-
terol, triglyceride, low density lipoprotein (LDL), high
density lipoprotein (HDL)] was done and sRAGE serum level
was also estimated by ELISA. Assessment of carotid intima-
media thickness by Carotid Dopplex Ultrasound was done at
the Ain Shams Radiology Department to estimate; Intimal
thickening, wall irregularities and any plaques (either soft, cal-
ciﬁed or ulcerated). Color Duplex was used to give an overview
of the carotid system to guide the application of the spectral
ﬂow at any suspected stenotic site. Sometimes B mode
ultrasound was used for better delineation of the region of
the pathway.
4. Statistical methods
The collected data were coded, tabulated, and statistically
analyzed using SPSS program (Statistical Package for Social
Sciences) software version 17.0. Descriptive statistics were
done for numerical parametric data as mean ± SD (standard
deviation) and minimum & maximum of the range and for
numerical non parametric data as median (IQR) [1st & 3rd
inter-quartile range], while they were done for categorical data
as number and percentage. Analysis was done for quantitative
variables using independent t-test in cases of two independent
groups with parametric data and Mann Whitney U in cases of
two independent groups with non parametric data. Analysis
was done for qualitative data using Chi square test for
independent variables while correlations were done using
Pearson Correlation for numerical parametric data, and
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categorical data. ROC curve was used to evaluate the value
of different tests that differentiate between certain groups.
The level of signiﬁcance was taken with p value < 0.05 being
signiﬁcant, otherwise it is not signiﬁcant.
5. Results
Patients and controls were matched for age and sex
(p> 0.05). None of the controls were prepubertal, 30%
were early pubertal stage (II, III Tanner classiﬁcation) and
70% were late pubertal stage (IV, V Tanner classiﬁcation).
On the other hand; 20% of patients were prepubertal,
43.4% were early pubertal and 36.6% were late pubertal
(p= 0.007). There was no signiﬁcant difference between
patients and controls as regards vital signs (p> 0.05).
Patients with type 1 DM had signiﬁcantly increased levels
of cholesterol, LDL and triglycerides and lower level ofFigure 1 (A) A localized soft atheroma causing 50% stenosis at the C
CCA. The localized small intraintimal cystic lesion could represent as
Table 1 Blood pressure values, laboratory and CIMT ﬁndings amo
Patients N= 60
SBP percentile
5–95 58(96.7%)
>95 2(3.3%)
DBP percentile
5–95 58(96.7%)
>95 2(3.3%)
Cholesterol (mg/dL) 149.4 ± 45.4
Triglycerides (mg/dL) 92.2 ± 30.0
LDL (mg/dL) 101.1 ± 35.5
HDL (mg/dL) 39.6 ± 9.3
sRAGE (pg/ml) 1765 ± 451.0
Mean CI MT (mm) 0.57 ± 0.14
Range (0.45–1.25)
Right CI MT (mm) 0.59 ± 0.19
Range (0.40–1.5)
Left CIMT (mm) 0.56 ± 0. 11
Range (0.40–1.0)
Wall abnormalities (n, %) 4 (13.3)
SBP; Systolic blood pressure. DBP; Diastolic blood pressure. LDL; Low
receptor for advanced glycation end product. CIMT; Carotid intema-me
# Chi square test.
^ Independent t-test.
* Signiﬁes the bold results.HDL (p< 0.05) (Table 1) with no signiﬁcant difference in
lipid proﬁle between the two groups of patients (p> 0.05).
sRAGE was signiﬁcantly higher among patients
(p 6 0.001). Mean CIMT was signiﬁcantly higher in patients
(p 6 0.001) (Table 1) especially in males (0.61 mm) compared
to females (0.52 mm) (p= 0.003). There was no signiﬁcant
difference between males and females as regards CIMT
among controls (p= 0.633). Four (13.3%) of patients had
carotid wall abnormalities in the form of atheroma in the
wall causing stenosis or intraintimal cystic lesions compared
to none of the controls (Fig. 1).
Both sRAGE and mean CIMT had good value to differen-
tiate between patients and controls. Mean CIMT of 0.52 mm
was the best cutoff value to differentiate between patients
and controls with low sensitivity (56%) and high speciﬁcity
(90%) while; sRAGE had 70% sensitivity and 70% speciﬁcity
to differentiate between patients and controls at a cutoff point
of 1475 pg/ml (Fig. 2).CA lumen. (B) Segmental regional intimal thickening of the right
sociated intimal cyst or ulceration.
ng patients and controls.
Controls N= 30 Test p
30(100%) 1.023# 0.312
0(0.0%)
30(100%) 1.023# 0.312
0(0.0%)
124.3 ± 15.8 3.886^ <0.001*
61.5 ± 9.1 7.466^ <0.001*
69.6 ± 6.8 7.099^ <0.001*
50.1 ± 10.3 5.002^ <0.001*
1408 ± 126.3 5.690^ <0.001*
0.48 ± 0.06 3.39^ <0.001*
0.40–0.60)
0.48 ± 0.06
(0.40–0.60)
0.48 ± 0.05
(0.40–0.60)
0 (0)
density lipoprotein. HDL; High density lipoprotein. sRAGE; Soluble
dia thickness.
 Figure 2 ROC curve for sRAGE and mean CIMT to differen-
tiate between patients and controls [AUC= 0.75 (95% CI:0.65–
0.85, p< 0.001) and 0.77 (95% CI:0.67–0.87, p< 0.001),
respectively.
Figure 3 Correlation between S-RAGE and CIMT in patients
and controls.
Figure 4 Correlation between mean CIMT
364 E.M. Sherif et al.A signiﬁcant direct correlation between sRAGE and mean
CIMT was detected only in the control group (r= 0.384,
p= 0.036).
Mean CIMT was directly correlated to age, weight, BMI,
systolic and diastolic blood pressures (p< 0.05) among
patients, while; a signiﬁcant direct correlation between sRAGE
and age, weight, height and BMI and an inverse correlation
between sRAGE and SBP were only detected in controls
(r= 0.562, p< 0.001).
There was a signiﬁcant direct correlation between mean
CIMT and UAE (r= 0.34, p= 0.007). There was a signiﬁcant
direct correlation between mean CIMT and cholesterol, LDL
and a signiﬁcant inverse correlation between CIMT and
HDL in both patients and controls (p< 0.05) (Fig. 3). sRAGE
was directly correlated to HDL (r= 0.3, p= 0.012) among
patients. Triglyceride was directly correlated to mean CIMT
only in controls (Fig. 4 and 5).
There was a signiﬁcant inverse correlation between mean
CIMT and insulin dose (r= 0.342, p= 0.007) and fre-
quency of monitoring (r= 0.408, p< 0.001) among patients
while; there was no correlation between either CIMT or
sRAGE and disease duration (r= 0.059, p= 0.66 and
r= 0.18, p= 0.17, respectively) or HbA1c% (r= 012,
p= 0.35 and r= 0.049, p= 0.71, respectively).
There was no signiﬁcant difference between group I and
group II of patients as regards demographic characteristics,
tanner score or vital signs (p> 0.05). Among group I of
patients; 6 (20%) patients had retinopathy, 10 (33.3%) had
nephropathy and 24 (80%) had neuropathy.
UAE was signiﬁcantly higher in group I with microalbu-
minuria and frank proteinuria detected in 26.7% and 6.7%,
respectively compared to none among group II. sRAGE was
higher among group II, but this did not reach a statistical sig-
niﬁcance (p= 0.18) (Table 2). Moreover; sRAGE was signiﬁ-
cantly higher in patients without retinopathy (1810 ± 444.5
pg/ml) than those with retinopathy (1360 ± 319 pg/ml)
(p< 0.05) while; it was higher among patients with nephropa-
thy (1798 ± 275.9 pg/ml) and those without neuropathy
(1835 ± 446 pg/ml), but this did not reach statistical signiﬁ-
cance (p> 0.05).
Mean CIMT was higher in group I but this did not reach
statistical signiﬁcance (p= 0.33) (Table 2). There was no sig-
niﬁcant difference between patients with and without retinop-
athy, nephropathy or neuropathy as regards CIMT (p> 0.05).with age and BMI percentiles in patients.
Figure 5 Correlation between mean CIMT and lipid proﬁle in patient and control groups.
Table 2 Laboratory and CIMT ﬁndings among patients’ groups.
Group I (n= 30) Group II (n= 30) Test value p
sRAGE (pg/ml) 1686.7 ± 432.7 1844.0 ± 465.3 1.356^ 0.180
Urinary albumin excretion (lg/mg) 25.4 (20.0–43.0) 20.0 (16.0–22.0) 3.293& <0.001*
Urinary albumin excretion (lg/mg)
<30 20 (66.7%) 30 (100.0%) 12.00# 0.002*
30–300 8 (26.7%) 0 (0.0%)
>300 2 (6.7%) 0 (0.0%)
Mean CIMT(mm) 0.60 ± 0.19 0.56 ± 0.08 0.976^ 0.333
Wall abnormalities 1 (3.3%) 3 (10.0%) 1.071# 0.301
sRAGE; soluble receptor for advanced glycation end product. CIMT; carotid intema-media thickness.
^ Independent t-test.
& Mann Whitney test.
# Chi square test.
* Signiﬁes the bold results.
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between group I and group II (AUC= 0.4 and 0.51,
respectively).
6. Discussion
Diabetes may render the arterial wall more susceptible to
harmful inﬂuences of circulating LDL cholesterol [9]. Diabet-
ics with endothelial dysfunction appear to be at particular risk
for developing early structural atherosclerotic changes [10].
In our study; total cholesterol, low density lipoprotein, tri-
glycerides were signiﬁcantly higher in patients than controls
while high density lipoprotein (HDL) was signiﬁcantly lower.
This is in agreement with other studies [11]. Others reported
no difference in lipid proﬁle between diabetics and controls
[12].
Our patients displayed signiﬁcantly higher sRAGE levels
than controls. Similar ﬁndings were reported by other studies
[13]. In addition; a French study investigating a small group
of patients with type 1 diabetes mellitus found elevated levels
of sRAGE in diabetic patients as compared to controls [14].
In contrast to our results Grossin et al. reported no signif-
icant difference in sRAGE level between controls and patients
with type 1 diabetes but without complications [15], while;
Basta et al. proved that plasma levels of sRAGE decreased
in diabetic patients [16].
sRAGE level was higher among the uncomplicated group
of patients despite that this did not reach a statistical signiﬁ-
cance; its level was higher among those without retinopathyor neuropathy suggesting a protective role; while it was higher
among those with nephropathy. Similar ﬁnding was reported
by Abdel-Aziz and El-Okely [17]. Nin et al. reported that
sRAGE levels tended to be higher in the presence and across
the levels of severity of retinopathy and nephropathy [18].
However; a number of studies have suggested that administra-
tion of sRAGE is protective against diabetic complications
[19–21]. Multiple studies indicated that RAGE is increased in
diseases of the kidney, including diabetes [22], as well in
advanced kidney disease. It is not clear if such high levels of
sRAGE were related to decreased clearance or for stimulation
by environmental toxic factors [23].
The blockade of the AGE-RAGE axis by administration of
sRAGE ameliorates neuronal dysfunction and reduces the
development of cellular capillaries and pericyte ghosts in
experimental diabetic retinopathy [24]. Furthermore; Kaji
et al. have shown that attenuation of the RAGE axis with
injection of sRAGE inhibits retinal leukostasis and retinal bar-
rier breakdown in the diabetic mice which are accompanied by
decreased expression of vascular endothelial growth factor
(VEGF) and intercellular cell adhesion molecule (ICAM) in
the retina [25]. On the other hand; Ng et al. reported that
the increased circulating level of plasma sRAGE would not
likely reduce the rate of DR progression in type 2 DM patients
[26].
In the current study there was a signiﬁcant direct correla-
tion between sRAGE and HDL in patients while; Katakami
et al. found that sRAGE had no signiﬁcant correlation with
triglycerides or HDL, but it was inversely correlated with total
366 E.M. Sherif et al.cholesterol. Also; they reported that sRAGE had no signiﬁcant
correlation with SBP in patients [27].
A signiﬁcant positive correlation was found between
sRAGE and CIMT only in controls. Similar results were
reported by others [16]. Their observation suggested that
higher levels of sRAGE may be a biomarker of a high degree
of vascular affections in non diabetic patients with coronary
artery disease.
Others revealed that continuous low levels of circulating
sRAGE were determinants of the progression of mean CIMT
independently of conventional risk factors and that plasma
levels of sRAGE were positively associated with macrovascu-
lar complications [18].
Similar to our ﬁnding; Yamagishi et al. reported that age
signiﬁcantly increased in proportion to the increasing levels
of sRAGE in non diabetic individuals [13], however; we
observed no signiﬁcant correlation with age, disease duration
or HbA1c% in patients. This is in agreement with Katakami
et al. and in contrast to Basta et al. who reported that plasma
sRAGE was inversely associated with HbA1c% [16,27].
In the present study, diabetic patients displayed a signiﬁ-
cant increase in mean CIMT compared to the normal control.
Similar results were reported in other studies [11,12,27]. Diabe-
tes predisposes to increased subclinical atherosclerosis at a
very early age but no plaque formations were observed in
any of the studied children [28].
This is in contrast to our ﬁndings, whereas; 4 (13.3%) of the
studied patients had carotid wall abnormalities in the form of
atheroma in the wall causing stenosis, and intraintimal cystic
lesions.
Similar to our ﬁnding; Margeirsdottir et al. found that ele-
vated CIMT among diabetic patients was the most prominent
in boys [11]. In contrast Jarvisalo et al. found no sex difference
in CIMT between children with diabetes and controls [28].
CIMT was directly correlated with age of patients, similar
ﬁnding was reported by many studies [12,29]. In contrast;
Katakami et al. found no signiﬁcant correlation between
CIMT and age in patients with type 1 diabetes [27].
Despite statistically insigniﬁcant; higher levels of CIMT
were detected among complicated patients. Many other studies
reported higher CIMT among diabetic patients with microvas-
cular complications indicating the association of diabetic
microangiopathy and macroangiopathy [12,30].
Similar to our ﬁnding; Gu¨l et al. found that CIMT was pos-
itively correlated with urinary albumin excretion, a sensitive
marker of diabetic nephropathy, while; Dalla Pozza et al.
failed to ﬁnd such correlation [12,31].
The direct correlation between mean CIMT with SBP,
DBP, cholesterol and LDL in our patients was supported by
many other studies [29,31,32], while; others denied such corre-
lations [11,12].
In agreement with our results; Margeirsdottir et al. showed
no association between IMT and duration of diabetes [11],
while; others found a direct correlation between CIMT and
duration of diabetes [12,28].
There was no signiﬁcant correlation between mean CIMT
and HbA1c% [11,12,28]. Dall Pozza et al. revealed a positive
correlation between mean CIMT and HbAlc% [31].
Improved blood glucose control obtained by intensive insu-
lin treatment is associated with delayed atherosclerosis devel-
opment and less cardiovascular events [29].7. Conclusion
Patients with type 1 diabetes mellitus are at risk of atherosclero-
sis marked by elevated CIMT which is related to increased age,
BMI, blood pressures, diabetic nephropathy and dyslipidemia.
It is not related to disease duration or metabolic control. Con-
comitant increase in sRAGE especially among the uncompli-
cated group of patients may suggest a therapeutic role of
sRAGE in the prevention of diabetic vascular complications.
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